Literature DB >> 7619443

The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants.

F T Cutts1, M Grabowsky, L E Markowitz.   

Abstract

High morbidity and mortality from measles among infants under 9 months of age is an obstacle to measles control in many developing countries. In this paper, we review 30 studies conducted on the serological response to measles vaccine in infants aged less than 9 months. Among children aged under 9 months, Edmonston Zagreb and AIK-C vaccines produce higher seroresponse rates than Schwarz vaccine of equivalent titre. For Edmonston Zagreb and Schwarz vaccine, seroresponse rates increase with increasing vaccine titre. The absolute rate of seroresponse to Edmonston Zagreb vaccine in 6-month old infants varied greatly between studies because of differences in methods of vaccine titer measurement, serological assays, definitions of seroresponse, and maternal antibody profiles of the populations studied. Seroconversion rates to Edmonston Zagreb or AIK-C vaccines at 6 months of age were generally similar to those to Schwarz vaccine at 9 months of age, but antibody levels were lower after vaccination below 9 months of age. Although the increased mortality documented in other studies after use of high titer vaccines in 4-6 month old infants led to withdrawal of these vaccines, this review of vaccine trials highlights the need for standardization of study methods and for a better understanding of the biological action of measles vaccines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619443     DOI: 10.1016/1045-1056(95)90018-7

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  22 in total

1.  Measles eradication: is it in our future?

Authors:  W A Orenstein; P M Strebel; M Papania; R W Sutter; W J Bellini; S L Cochi
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 2.  Biological feasibility of measles eradication.

Authors:  William J Moss; Peter Strebel
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

Review 3.  Effectiveness of measles vaccination and vitamin A treatment.

Authors:  Christopher R Sudfeld; Ann Marie Navar; Neal A Halsey
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

Review 4.  Progress in the elimination of measles and congenital rubella in Central Italy.

Authors:  Angela Bechini; Miriam Levi; Sara Boccalini; Emilia Tiscione; Donatella Panatto; Daniela Amicizia; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

5.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

Review 7.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

8.  Assessing measles vaccine failure in Tianjin, China.

Authors:  Nina B Masters; Abram L Wagner; Yaxing Ding; Ying Zhang; Matthew L Boulton
Journal:  Vaccine       Date:  2019-05-08       Impact factor: 3.641

9.  Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.

Authors:  Kaitlin Rainwater-Lovett; Hope C Nkamba; Mwangelwa Mubiana-Mbewe; Carolyn Bolton-Moore; William J Moss
Journal:  J Infect Dis       Date:  2013-08-02       Impact factor: 5.226

10.  Measles still has a devastating impact in unvaccinated populations.

Authors:  William J Moss
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.